Open access
Open access
Powered by Google Translator Translator

Covid-19 (Public Health Issues)

M-A: Observational data on the effectiveness of COVID-19 vaccines.

30 Nov, 2021 | 08:37h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 


WHO Update on Omicron + Several Articles on the Subject.

28 Nov, 2021 | 21:38h | UTC

Update on Omicron – World Health Organization

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern – World Health Organization

See also:

Omicron COVID-19 variant: Africa CDC statement

Expert reaction to B.1.1.529 variant situation in South Africa; and UK travel restrictions in response – Science Media Centre

Threat Assessment Brief: Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA – European Centre for Disease Prevention and Control

‘Patience is crucial’: Why we won’t know for weeks how dangerous Omicron is – Science

Scientists rapidly identified the Omicron variant. But firm answers about its impact could take weeks – STAT

New Covid variant: Will new measures against Omicron work? – BBC

Vaccine inequity and hesitancy made the Omicron variant more likely, scientists say – CNN

Travel bans aren’t the answer to stopping new COVID variant Omicron – The Conversation

Scientists sharing Omicron data were heroic. Let’s ensure they don’t regret it – The Guardian

The Omicron variant reveals the true global danger of ‘vaccine apartheid’ – The Guardian

We Know Almost Nothing About the Omicron Variant – The Atlantic

Covid: New Omicron variant not a disaster, says Sage scientist – BBC

New Covid variant: Will new measures against Omicron work? – BBC

World is put on high alert over the Omicron coronavirus variant – CNN

Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant – Moderna

Omicron is the new COVID kid on the block: five steps to avoid, ten to take immediately – The Conversation

What’s known and unknown about Omicron, the coronavirus variant identified in South Africa – STAT

The new variant is worrying – but it doesn’t change how we tackle Covid – The Guardian

Omicron: everything you need to know about new Covid variant – The Guardian

Omicron variant unlikely to reboot Covid in UK, expert says – The Guardian

UK detects Omicron cases, as more countries eye new COVID-19 variant – CIDRAP

New COVID variant alarms researchers, triggers travel bans – CIDRAP

The omicron variant spreads across Europe as new travel bans take effect – NPR

What to know about omicron, the new COVID variant – NPR

What we know about the Omicron variant – CNN

The new Omicron variant is a pandemic gut check – CNN

Newly discovered Covid-19 variant B.1.1.529 is ‘red flag’ but US needs to learn more, Fauci says – CNN

Omicron, a new Covid-19 variant with high number of mutations, sparks travel bans and worries scientists – CNN

What to know about the omicron variant of the coronavirus – The Washington Post

 

Commentary on Twitter (thread – click for more)

 


Omicron Variant: Videos with opinions on the subject.

28 Nov, 2021 | 21:33h | UTC

 


[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

28 Nov, 2021 | 21:30h | UTC

News Release: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Commentary: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Commentaries on Twitter

 


Milestone Moment for Pandemic Treaty in Geneva – Calls for Tough Decisions by Countries.

28 Nov, 2021 | 21:28h | UTC

Milestone Moment for Pandemic Treaty in Geneva – Calls for Tough Decisions by Countries – Health Policy Watch

See also:

Countries prepare for pandemic treaty decision – The Lancet

WHO nears consensus on future international pact to prevent pandemics – diplomats – Reuters

The WHO is seeking a new treaty on handling future pandemics. It could be a hard sell – NPR

 

Commentary on Twitter

 


European countries mandate medical-grade masks over homemade cloth face coverings.

28 Nov, 2021 | 21:26h | UTC

European countries mandate medical-grade masks over homemade cloth face coverings – CNN

 


EMA recommends approval of Pfizer-BioNTech vaccine for children aged 5 to 11.

26 Nov, 2021 | 08:47h | UTC

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 – European Medicines Agency

Related:

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

What COVID vaccines for young kids could mean for the pandemic.

CDC advisers endorse Pfizer’s Covid-19 vaccine for kids 5-11.

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

 

Commentary on Twitter

 


Heavily mutated coronavirus variant puts scientists on alert – “Researchers are racing to determine whether a fast-spreading variant in South Africa poses a threat to COVID vaccines’ effectiveness”.

26 Nov, 2021 | 08:42h | UTC

Heavily mutated coronavirus variant puts scientists on alert – Nature

See also:

Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC

WHO calls special meeting to discuss new Covid variant found in South Africa with ‘a large number of mutations’ – CNBC

New COVID-19 Variant With Multiple Concerning Mutations Identified in Southern Africa – Health Policy Watch

Scientists warn of new Covid variant with high number of mutations – The Guardian

South Africa detects new COVID variant with many mutations – MedicalXpress

 

Related commentary on Twitter (thread – click for more)

 


Editorial: Vax the world.

26 Nov, 2021 | 08:40h | UTC

Vax the world – Science

 

Commentary from the author on Twitter

 


M-A: Comparing the clinical efficacy of COVID-19 vaccines.

26 Nov, 2021 | 08:37h | UTC

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis – Scientific Reports

 


[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

 

Commentary from the author on Twitter (thread – click for more)

 


WHO Interim statement on COVID-19 vaccination for children and adolescents.

25 Nov, 2021 | 10:49h | UTC

Interim statement on COVID-19 vaccination for children and adolescents – World Health Organization

 


A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

Related: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

 


COVID-19 reinfection: the role of natural immunity, vaccines, and variants.

25 Nov, 2021 | 10:45h | UTC

COVID-19 reinfection: the role of natural immunity, vaccines, and variants – Journal of Community Hospital Internal Medicine Perspectives

Related: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

 


Perspective: COVID-19 vaccine makers plan for annual boosters, but it’s not clear they’ll be needed.

25 Nov, 2021 | 10:43h | UTC

COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll Be Needed – JAMA

 


Do vaccines protect against long COVID? What the data say – “Vaccines reduce the risk of developing COVID-19 — but studies disagree on their protective effect against long COVID”.

25 Nov, 2021 | 10:41h | UTC

Do vaccines protect against long COVID? What the data say – Nature

Related:

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Commentary on Twitter

 


Cuba’s bet on home-grown COVID vaccines is paying off.

25 Nov, 2021 | 10:39h | UTC

Cuba’s bet on home-grown COVID vaccines is paying off – Nature

 


WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19.

24 Nov, 2021 | 08:51h | UTC

News Release: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Guideline: Living guidance for clinical management of COVID-19 – World Health Organziation

Related:

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

 


Opinion from thirty two ministers of health: The world must act now to be prepared for future health emergencies.

24 Nov, 2021 | 08:49h | UTC

The world must act now to be prepared for future health emergencies – The BMJ

Related:

Viewpoint | Strengthening global health security and reforming the international health regulations: making the world safer from future pandemics.

Perspective | Learning from crisis: building resilient systems to combat future pandemics.

Systematic review: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics.

Opinion | The future of pandemic preparedness: agile coordination around clinical trials.

UN Report: Preventing the Next Pandemic – Zoonotic Diseases and How to Break the Chain of Transmission

 

Commentary on Twitter

 


Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.

24 Nov, 2021 | 08:47h | UTC

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA – The Lancet

Related: WHO Guidance for improving acceptance and uptake of COVID-19 vaccines

 


[Preprint] Systematic Review: Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease – “effectiveness against COVID-19 severe disease remained high (>70%) in most studies in the six months after full vaccination, although it did decrease some (on average, 8-10 percentage points) between one and six months after full vaccination”.

23 Nov, 2021 | 08:57h | UTC

Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression – Preprints with The Lancet – SSRN

Related:

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 


Populational study in France did not show an increased incidence of acute myocardial infarction, stroke, and pulmonary embolism following the Pfizer vaccine.

23 Nov, 2021 | 08:51h | UTC

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older – JAMA

 


Scientists mystified, wary, as Africa avoids COVID disaster.

23 Nov, 2021 | 08:47h | UTC

Scientists mystified, wary, as Africa avoids COVID disaster – Associated Press

 


United States FDA clears COVID vaccine boosters for all adults over 18 – Pfizer & Moderna 6 months after second jab.

21 Nov, 2021 | 23:17h | UTC

United States FDA Clears COVID Vaccine Boosters for All Adults Over 18 – Pfizer & Moderna 6 Months After Second Jab – Health Policy Watch

See also:

FDA expands emergency authorization for Covid-19 booster shots to all adults – STAT

FDA, CDC advisors approve COVID boosters for all US adults – CIDRAP

FDA Approves Both Pfizer, Moderna Boosters for All Adults – HealthDay

 


Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – “The IFR was low for people younger than 51 years without comorbidity during the two waves (combined IFR = 3.36 per 100,000 infections)”.

21 Nov, 2021 | 23:12h | UTC

Estimation of SARS-CoV-2 infection fatality rate by age and comorbidity status using antibody screening of blood donors during the COVID-19 epidemic in Denmark – The Journal of Infectious Diseases

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.